The study was evaluating the potential of crenezumab to slow or prevent Alzheimer’s disease in cognitively unimpaired patients who carry the Presenilin 1 E280A mutation. The data will be presented at the AAIC in Aug 2022
The study did not show significant clinical benefit in 1EPs i.e, assessing the rate of change in cognitive abilities or episodic memory function, measured by the API ADAD composite cognitive score & the Free and Cued Selective Reminding Test (FCSRT) Cueing Index
The study API ADAD (Colombia) enrolled 252 people of which two-thirds participants carried a specific mutation which causes cognitive impairment. Participants were randomized to receive crenezumab or PBO over 5 to 8yrs. The study was supported by the National Institute on Aging, generous philanthropic contributions to Banner Alzheimer’s Foundation
Ref: Businesswire | Image: Genentech
